{"entity":{"id":"wen-zhao-zhong","kind":"person","name":"Wen-Zhao Zhong","aka":[],"tldr":"Thoracic surgeon-scientist and hospital Vice President who led the ADJUVANT/CTONG1104 trial establishing adjuvant EGFR-TKI therapy in resected lung cancer.","summary":"Wen-Zhao Zhong is Vice President of Guangdong Provincial People's Hospital and a thoracic surgical oncologist at the Guangdong Lung Cancer Institute. He was first author of the ADJUVANT/CTONG1104 phase 3 trial, which compared adjuvant gefitinib with chemotherapy in resected EGFR-mutant non-small-cell lung cancer, and has published extensively on perioperative targeted therapy through the Chinese Thoracic Oncology Group.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.gdghospital.org.cn/thecurrentleader/list.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhong+WZ%5BAuthor%5D"}],"tags":["clinician-scientist","leadership","lung cancer","thoracic surgery"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["guangdong-provincial-peoples-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice President and Party Standing Committee Member","institutionId":"guangdong-provincial-peoples-hospital","specialisms":["Thoracic surgery","Lung cancer","EGFR-mutant NSCLC","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.gdghospital.org.cn/thecurrentleader/list.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhong+WZ%5BAuthor%5D"}],"papers":[{"title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study","journal":"Lancet Oncology","year":2018,"url":"https://doi.org/10.1016/S1470-2045(17)30729-5","doi":"10.1016/S1470-2045(17)30729-5"},{"title":"Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial","journal":"Journal of Clinical Oncology","year":2021,"url":"https://doi.org/10.1200/JCO.20.01820","doi":"10.1200/JCO.20.01820"}]},"route":"/people/wen-zhao-zhong/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"institution":[{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/"}]}}